World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 10 December 2019
Main ID:  EUCTR2013-005489-20-SE
Date of registration: 11/07/2014
Prospective Registration: Yes
Primary sponsor: PTC Therapeutics, Inc.
Public title: Extension study of ataluren in patients with nonsense mutation Duchenne and Becker muscular dystrophy
Scientific title: A Phase 3 Extension Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy
Date of first enrolment: 22/08/2014
Target sample size: 220
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-005489-20
Study type:  Interventional clinical trial of medicinal product
Study design: 
Controlled: no
Randomised:
Open:
Single blind:
Double blind:
Parallel group:
Cross over:
Other:
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Australia Belgium Brazil Bulgaria Canada Chile Czech Republic France
Germany Israel Italy Korea, Republic of Spain Sweden Switzerland Turkey
United Kingdom United States
Contacts
Name: Clinical Trial Operations   
Address:  3 rue des Longs Prés 92100 Boulogne-Billancourt France
Telephone:
Email: clinicaltrialinformation@voisinconsulting.com
Affiliation:  Voisin Consulting
Name: Clinical Trial Operations   
Address:  3 rue des Longs Prés 92100 Boulogne-Billancourt France
Telephone:
Email: clinicaltrialinformation@voisinconsulting.com
Affiliation:  Voisin Consulting
Key inclusion & exclusion criteria
Inclusion criteria:
1. Completion of study treatment in the previous Phase 3, double-blind study protocol (Protocol PTC124-GD-020-DMD).
2. Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial.
3. In subjects who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and 6-week follow-up period.
4. Willingness and ability to comply with scheduled visits, ataluren administration plan, study procedures, laboratory tests, and study restrictions.
Are the trial subjects under 18? yes
Number of subjects for this age range: 220
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Known hypersensitivity to any of the ingredients or excipients of the study drug (Litesse® UltraTM [refined polydextrose], polyethylene glycol 3350, Lutrol® micro F127 [poloxamer 407], mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla, Cab-O-Sil® M5P [colloidal silica], magnesium stearate).
2. Ongoing participation in any other therapeutic clinical trial.
3. Prior or ongoing medical condition (eg, concomitant illness, psychiatric condition, behavioral disorder, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator’s opinion, could adversely affect
the safety of the patient, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.


Age minimum:
Age maximum:
Gender:
Female: no
Male: yes
Health Condition(s) or Problem(s) studied
Nonsense mutation dystrophinopathy
MedDRA version: 18.1 Level: PT Classification code 10059117 Term: Becker's muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 18.1 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disorders
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Intervention(s)

Product Name: ataluren
Product Code: PTC124
Pharmaceutical Form: Powder for oral suspension
INN or Proposed INN: ataluren
CAS Number: 775304-57-9
Current Sponsor code: PTC124
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-

Product Name: ataluren
Product Code: PTC124
Pharmaceutical Form: Powder for oral suspension
INN or Proposed INN: ataluren
CAS Number: 775304-57-9
Current Sponsor code: PTC124
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-

Product Name: ataluren
Product Code: PTC124
Pharmaceutical Form: Powder for oral suspension
INN or Proposed INN: ataluren
CAS Number: 775304-57-9
Current Sponsor code: PTC124
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1000-

Primary Outcome(s)
Primary end point(s): Safety profile characterized by type, frequency, severity, timing, and relationship to ataluren of any adverse events or laboratory abnormalities.
Timepoint(s) of evaluation of this end point: Screening visit, every 12 weeks up to 6 weeks post-treatment.

Secondary Objective: Physical:
• To determine the effect of ataluren on ambulation in subjects who are ambulatory
• To evaluate the effect of ataluren on proximal muscle function in subjects who are able to perform timed function tests
• To evaluate the effect of ataluren on physical function in subjects who are able to perform the North Star Ambulatory Assessment
• To evaluate the effect of ataluren on upper limb function
Pulmonary function:
• To evaluate the effect of ataluren on pulmonary function
Patient-reported outcomes:
• To determine the effect of ataluren on health-related quality of life (HRQL) as reported by subjects and parents/caregivers
• To assess the effect of ataluren on activities of daily living
Exposure:
• To assess long-term ataluren plasma exposure
Main Objective: To evaluate the long-term safety of ataluren in boys with nonsense mutation dystrophinopathy, as determined by adverse events and laboratory abnormalities.
Secondary Outcome(s)

Secondary end point(s): Physical:
1. Change in ambulation as measured by the 6MWT
2. Change in proximal muscle function as assessed by timed function tests (time to rise from supine position, time to run 10 meters, and time to climb/descend 4 stairs)
3. Change in physical function as assessed by the North Star Ambulatory Assessment
4. Change in motor performance of the upper limb as measured by the Performance Upper Limb (PUL)
Pulmonary function:
5. Change in pulmonary function as measured by spirometry (eg. FVC, FEV1)
Patient-reported outcomes:
6. Change in patient- and parent/caregiver-reported HRQL as measured by the PODCI Transfer/Basic Mobility and Sports/Physical Functioning scores
7. Change in patient and parent/caregiver reported activities of daily living
Exposure:
8. Pre-dose ataluren plasma concentrations prior to morning ataluren administration at each clinic visit as assessed by a validated bioanalytical method
Safety:
9. Change from baseline in other safety parameters (eg, vital signs)

Timepoint(s) of evaluation of this end point: 1, 2, 3, 4, 6, 7, 8: Screening visit and every 12 weeks up to week 144
5: Screening visit, at weeks 24, 48, 72, 96, 120, 144
9: Screening visit, every 12 weeks up to 6 weeks post-treatment
Secondary ID(s)
PTC124-GD-020e-DMD
68431
NCT02090959
Source(s) of Monetary Support
PTC Therapeutics, Inc.
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey